Notice to Stakeholders: Statement on the Investigational Use of Marketed Drugs in Clinical Trials

Notice to Stakeholders: Statement on the Investigational Use of Marketed Drugs in Clinical Trials This statement provides guidance to clinical trial applicants about the investigational use of marketed drugs within clinical trials in Canada. 2022-06-07 Health Canada open-ouvert@tbs-sct.gc.ca Health and Safetyclinical trialinvestigational Use-of-Marketed-DrugsUse-of-Marketed-Drugs in clinical-trialsguidanceclinical trial applicants Notice to Stakeholders: Statement on the Investigational Use of Marketed Drugs in Clinical TrialsHTML https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/notice-statement-investigational-use-marketed-drugs-clinical-trials.html Notice to Stakeholders: Statement on the Investigational Use of Marketed Drugs in Clinical TrialsHTML https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/annonces/avis-declaration-utilisation-experimentale-medicaments-commercialises-essais-cliniques.html

This statement provides guidance to clinical trial applicants about the investigational use of marketed drugs within clinical trials in Canada.

Data and Resources

Similar records